Article date: September 2011
There are insufficient data to determine the size of the risk or any difference in risk between classes of antipsychotics or between individual antipsychotics.
UK product information for all antipsychotics will be updated to include consistent information about this risk.
Advice for healthcare professionals:
- following maternal use of antipsychotics in the third trimester, examine newborns for symptoms which may include: agitation; hypertonia; hypotonia; tremor; somnolence; feeding problems; and respiratory distress
- symptoms may vary in severity and duration, and they should be monitored and treated (if necessary) on an individual basis
- expectant mothers should be counselled about the benefits and risks of antipsychotic treatment during pregnancy
Please report suspected adverse events related to the use of antipsychotics during pregnancy through the Yellow Card Scheme at www.yellowcard.gov.uk
Report from the European Pharmacovigilance Working Party
US Food and Drug Administration safety information on antipsychotic drugs and treatment during pregnancy
Summaries of product characteristics
BNF section 4.2.1 Antipsychotic drugs
Article citation: Drug Safety Update Sept 2011, vol 5 issue 2: A2.
Published 11 December 2014